帕金森氏症市場:KOL的洞察

本報告提供全球帕金森氏症市場相關調查，提供市場概要，以及已通過核准治療方法，開發平台趨勢，未來預測等資訊。

目錄

摘要整理

現在及未來的治療流程

調查目的

對帕金森氏症的目前治療方法

• 重要的洞察概要

已通過核准治療方法

• 多巴胺促效劑
• 固定用量組合藥物
• MAO-B抑制劑
• COMT抑制劑
• 其他

開發平台(管線)治療方法

• 多巴胺促效劑
• 固定用量聯合治療
• 其他的作用機制
• 初期階段的藥物候補
• 其他的作用機制/開發平台(管線)候補
• 數位螢幕/穿戴式

未來的治療範例

• 重要的洞察概要

附錄

Where do KOLs see an opportunity for GSK's transdermal dopamine agonist ropinirole? How do KOLs assess the competing benefits of AbbVie's Duopa/Duodopa and levodopa/carbidopa fixed dose combinations? What challenges and benefits do experts see for AbbVie's ABBV-951 pipeline subcutaneous levodopa + carbidopa combination? Why do KOLs say disease modification by inhibiting alpha-synuclein remains a complex proposition? KOLs critically assess the prospects of launched and pipeline therapies.

Table of Contents

Executive summary (12)

Current and future treatment algorithm

Research objectives (3)

Current practice for treating Parkinson's disease (3)

• Key insights summary (3)
  • First-line treatment for PD is usually levodopa, a dopamine agonist or a MAO-B inhibitor, depending on symptom severity, age, health, concomitant diseases and patient formulation preference (1)

Approved therapies (69)

• Dopamine agonists (21)
  • Key insights summary (21)
• Fixed-dose combination agents (17)
  • Key insights summary (17)
• MAO-B inhibitors (12)
  • Key insights summary (12)
• COMT inhibitors (11)
  • Key insights summary (11)
• Other agents (8)
  • Key insights summary (8)

Pipeline therapies (133)

• Dopamine agonists (21)
  • LY03003 (rotigotine intramuscular injection; Luye Pharma Group) (8)
  • Aplindore (DAB 452; Seelos Therapeutics) (6)
  • Tavapadon (Cerevel Therapeutics) (7)
• Fixed-dose combination therapies (26)
  • Levodopa + carbidopa subcutaneous infusions (2)
  • ABBV-951 (Produodopa; foslevodopa + foscarbidopa subcutaneous infusion; AbbVie) (8)
  • ND0612 (levodopa + carbidopa subcutaneous infusion; NeuroDerm/Mitsubishi Tanabe Pharma) (4)
  • IPX203 (levodopa + carbidopa extended-release; Amneal Pharmaceuticals) (5)
  • P2B001 (pramipexole + rasagiline; Pharma Two B) (7)
• Other modes of action (33)
  • Levodopa Cyclops dry powder inhaler (PureIMS) (8)
  • DNL151 (Denali Therapeutics/Biogen) (6)
  • Nabilone FDT (AOP Orphan Pharmaceuticals) (6)
  • Mesdopetam (Integrative Research Laboratories) (7)
  • Buntanetap (R-phenserine; Posiphen; Annovis Bio) (6)
• Early-phase drug candidates (38)
  • Alpha-synuclein inhibitors (2)
  • UCB0599 (UCB) (1)
  • PRX002 (prasinezumab; Roche) (1)
  • ENT-01 (kenterin; Enterin) (1)
  • ION464 (Ionis Pharma/Biogen) (6)
  • Repurposed drugs (2)
  • Tasigna (nilotinib; Novartis) (8)
  • Cell transplantation therapies (2)
  • Cell therapies (GRF6021 [Alkahest/Grifols], NeurotrophinCell [Living Cell Technologies]) (7)
  • Viral gene delivery approaches (8)
• Other mechanisms of action/pipeline candidates (8)
  • Key insights summary (8)
• Digital monitors/wearables (7)
  • Key insights summary (7)

Future treatment paradigm (7)

• Key insights summary (7)
  • With disease modification a slim prospect in the next five years, the focus may remain on better management of fluctuations, dyskinesia and other pressing needs like frozen gait or dementia (5)

Appendix (4)

• KOL details (4)
  • KOLs from North America (1)
  • KOLs from Europe (2)